Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14816145 | 0.82 | MAPK1 (0.48) | ALDH1A1TSHRMAPK1ALOX15TAAR1 | |
| SCHEMBL13610411 | 0.76 | ALDH1A1 (0.52) | ALDH1A1TSHRMAPK1ALOX15TAAR1 | |
| Trifluoromethylbenzene SCHEMBL28660823 | 0.75 | ALDH1A1 (0.67) | ALDH1A1TSHRMAPK1ALOX15TAAR1 | |
| SCHEMBL10202598 | 0.75 | MAPK1 (0.46) | ALDH1A1TSHRMAPK1ALOX15TAAR1 | |
| SCHEMBL3621303 | 0.75 | ALDH1A1 (0.58) | ALDH1A1TSHRMAPK1ALOX15TAAR1 | |
| SCHEMBL6342232 | 0.75 | ALDH1A1 (0.58) | ALDH1A1TSHRMAPK1ALOX15TAAR1 | |
| SCHEMBL13554 | 0.75 | ALDH1A1 (0.58) | ALDH1A1TSHRMAPK1ALOX15TAAR1 | |
| SCHEMBL17885872 | 0.75 | ALDH1A1 (0.58) | ALDH1A1TSHRMAPK1ALOX15TAAR1 | |
| SCHEMBL23789538 | 0.72 | ALDH1A1 (0.55) | ALDH1A1TSHRMAPK1ALOX15TAAR1 | |
| SCHEMBL960581 | 0.72 | MAPK1 (0.70) | ALDH1A1TSHRMAPK1ALOX15TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257842-B1 | THERAPEUTIC USE OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2020-11-18 | — | — | EP | disclosed |
| CN-104523668-B | High-purity 2- [4- (3-or 2-fluorobenzyloxy) benzylamino ] propanamides and use thereof | 纽朗制药有限公司 | 2020-06-09 | — | — | CN | disclosed |
| EP-3257842-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2017-12-20 | — | — | EP | disclosed |
| EP-2229351-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2017-11-08 | — | — | EP | disclosed |
| EP-2474521-B1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | NEWRON PHARM SPA (IT) | 2016-08-10 | — | — | EP | disclosed |
| CN-103284984-B | The method producing 2-[4-(3-and 2-fluorine benzyloxy) benzyl amino] Propionamides | 纽朗制药有限公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-104523668-A | High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof | NEWRON PHARM SPA | 2015-04-22 | — | — | CN | disclosed |
| EP-2029524-B1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | NEWRON PHARM SPA (IT) | 2014-11-26 | — | — | EP | disclosed |
| CN-101896456-B | Process for producing 2- [4- (3-or 2-fluorobenzyloxy) benzylamino ] propanamides with high purity | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-10-22 | — | — | CN | disclosed |
| US-8846763-B2 | High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-09-30 | — | — | US | disclosed |
| US-20120157712-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-06-21 | — | — | US | disclosed |
| US-8076515-B2 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-12-13 | — | — | US | disclosed |
| US-20100324141-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-23 | — | — | US | disclosed |
| CN-101896456-A | Process for producing 2- [4- (3-or 2-fluorobenzyloxy) benzylamino ] propanamides with high purity | NEWRON PHARM SPA | 2010-11-24 | — | — | CN | disclosed |
| EP-2229351-A1 | PROCESS FOR THE PRODUCTION OF 2-Ý4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO¨PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| CN-101472880-A | Process for the production of 2- [ 4- (3-and 2-fluorobenzyloxy) benzylamino ] propanamides | NEWRON PHARM SPA (IT) | 2009-07-01 | — | — | CN | disclosed |
| WO-2009074478-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | US | disclosed |
| EP-2029524-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | Newron Pharmaceuticals S.p.A. (IT) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007147491-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLU0R0BENZYL0XY) BENZYLAMIN0] PROPAN AMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | PTMA, PSMB2, PDGFRA | ALDH1A1 593/4885TSHR 2646/4885MAPK1 3572/4885 |
| US-20100324141-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF | PDE7A, PDE8B, PDE9A | ALDH1A1 150/4885TSHR 2195/4885MAPK1 4001/4885 |
| US-20120157712-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | PTMA, PSMB2, PDGFRA | ALDH1A1 593/4885TSHR 2646/4885MAPK1 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.